Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Traditional Medicine First To Obtain Halal Certification

This article was originally published in PharmAsia News

Executive Summary

Guangzhou Qixing Pharmaceutical has obtained Halal certification for its Hua Tuo Zaizao Pills, a natural preparation of plant origin for treating and preventing cardiovascular and cerebrovascular diseases. The TCM is China's first to receive the certification for food prepared in a manner prescribed by Islamic law, opening doors to an international Muslim market. The patented pill has been the country's largest therapeutic drug export for eight years, with distribution covering 27 countries in Southeast Asia, Eastern Europe, South America, and Oceania. Guangzhou Qixing's compliance with international drug standards and its latest certification set a role model for other aspiring domestic pharmaceutical enterprises. (Click here for more - Chinese Language)

You may also be interested in...



Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 

Pfizer Confirms EU Pegfilgrastim Launch Plans

Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel